Multiple myeloma
Conditions
Interventions
Pomalidomide combined with low-dose dexamethasone group :None
Pomalidomide combined with cyclophosphamide and dexamethasone group :None
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. >= 18 years old, male or female, diagnosed with relapsed or refractory multiple myeloma according to the IMWG diagnostic criteria; 2. When the patient starts using pomalidomide, the hematology routine meets the following requirements: ANC>=500/µL, PLT>=50000/µL; the researchers believe that patients who can benefit from the pomalidomide-containing regimen.
Exclusion criteria
Exclusion criteria: 1. Patients who have had allergic reactions to immunomodulators similar to pomalidomide, dexamethasone or the components contained in the drug; 2. Patients with active new thrombosis or unwilling to undergo antithrombotic therapy; 3. Patients with peripheral neuropathy >= grade 3; 4. Severe mental illness; patients who are judged unsuitable for enrollment after the investigator's evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;progression free survival; | — |
Countries
China
Contacts
Public ContactFang Baijun
Henan Cancer Hospital
Outcome results
None listed